Completed PHASE1 INTERVENTIONAL 5-arm NCT05247203

Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus

A Phase I, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Telitacicept in Chinese Subjects With Systemic Lupus Erythematosus (SLE)

Sponsor: RemeGen Co., Ltd.

Conditions Systemic Lupus Erythematosus

Interventions Telitacicept standard therapy

Updated 7 times since 2022 Last updated: Dec 5, 2023 Started: May 11, 2022 Primary completion: Oct 25, 2023 Completion: Nov 13, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05247203, this PHASE1 trial focuses on Systemic Lupus Erythematosus and remains completed. Sponsored by RemeGen Co., Ltd., it has been updated 7 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2024 — Jul 2024 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Dec 2023 — Jan 2024 [monthly]

Recruiting PHASE1
Oct 2023 — Dec 2023 [monthly]

Recruiting PHASE1

▶ Show 2 earlier versions

Jun 2022 — Oct 2023 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Mar 2022 — Jun 2022 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

RemeGen Co., Ltd.

Data source: RemeGen Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baoding, China , Beijing, China , Bengbu, China , Changsha, China , Guangzhou, China , Guilin, China , Hangzhou, China , Hefei, China , Jinan, China , Kunming, China and 7 more locations